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PhosphorylationC-Raf is amember of the Ras–Raf–MEK–ERKmitogen-activated protein kinase (MAPK) signaling pathway that
plays key roles in diverse physiological processes and is upregulated in many human cancers. C-Raf activation
involves binding to Ras, increased phosphorylation and interactions with co-factors. Here, we describe
a Ras-independent in vivo pathway for C-Raf activation by its downstream target MEK. Using 32P-metabolic
labeling and 2D-phosphopeptide mapping experiments, we show that MEK increases C-Raf phosphorylation
by up-to 10-fold. This increase was associated with C-Raf kinase activation, matching the activity seen with
growth factor stimulation. Consequently, coexpression of wildtype C-Raf and MEK was sufﬁcient for full and
constitutive activation of ERK. Notably, the ability of MEK to activate C-Raf was completely Ras independent,
since mutants impaired in Ras binding that are irresponsive to growth factors or Ras were fully activated by
MEK. The ability of MEK to activate C-Raf was only partially dependent on MEK kinase activity but required
MEK binding to C-Raf, suggesting that the binding results in a conformational change that increases C-Raf sus-
ceptibility to phosphorylation and activation or in the stabilization of the phosphorylated-active form. These
ﬁndings propose a novel Ras-independentmechanism for activating the C-Raf and theMAPK pathwaywithout
the need for mutations in the pathway. This mechanism could be of signiﬁcance in pathological conditions or
cancers overexpressing C-Raf and MEK or in conditions where C-Raf–MEK interaction is enhanced due to the
down-regulation of RKIP and MST2.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The mammalian serine/threonine kinase family, Raf, consists of
three highly conserved members: A-Raf, B-Raf and C-Raf/c-Raf-1
[1–4]. Raf is part of the phosphorylation cascade of the mitogen-
activated protein kinase (MAPK) pathway, Ras–Raf–MEK–ERK [5–7].
The MAPK pathway is involved in the regulation of a large variety of
cellular physiological functions and its uncontrolled activation leads
to cell transformation [8]. Importantly, increased activation of the
MAPK pathway is seen in more than 50% of all human cancers, either
through the abnormal activation of growth factor receptors or through
mutations in the pathway itself. For example, 30% of all human cancers
carry an activating Ras mutation while many others carry activating
mutations in the B-Raf gene, predominantly in melanomas and thyroid
cancers [9–11].of Mississippi Medical Center,
el.: +1 601 815 6765; fax: +1
l rights reserved.C-Raf activation involves multiple protein–protein interactions
and phosphorylation events that are not yet fully understood [1,4].
The initial step following stimulation of cells with various growth
factors includes the accumulation of the active, GTP-bound Ras,
which binds and recruits cellular inactive C-Raf to the plasma mem-
brane. Two C-Raf domains mediate the binding of GTP-Ras to C-Raf:
a Ras-binding domain, RBD, amino acids 57–131 and a zinc ﬁnger
cysteine-rich domain, CRD, amino acids 139–184 (Fig. 1) [1,12–14].
The binding to Ras is thought to enforce a conformational change in
C-Raf, opening the molecule to phosphorylation and other potential
activating sequences at the plasma membrane [1,4,15]. Following ac-
tivation, C-Raf dissociates from Ras and can be found in the cytoplasm
associated with several scaffold proteins including the regulatory
protein, 14-3-3, which is required for maintaining the active state of
C-Raf [16,17].
Phosphorylation of C-Raf during the activation process is critical
for conferring the active conformation and mutation of key phos-
phorylation sites or their dephosphorylation inactivates C-Raf kinase
activity. Of the known C-Raf phosphorylation sites, phosphorylations
at S338/9 and Y340/1, located in a conserved regulatory region, and
phosphorylations at S471 and S491/4, located in the catalytic domain
(Fig. 1), are thought to have themost signiﬁcant role in C-Raf activation
Fig. 1. C-Raf domains and known phosphorylation sites. Indicted are the C-Raf phosphorylation sites and the kinases that have been reported to phosphorylate these sites, the kinase
domain and the Ras binding domains: RBD (Ras binding domain) and CRD (cysteine rich domain). CR1, 2 and 3 are conserved regions among the Raf family members. See text for
further details.
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interaction of C-Raf with the 14-3-3 proteins [15,20]. Several of the
other identiﬁed phosphorylation sites seem to play a negative role in
C-Raf regulation, including S43 and S259, which can be phosphorylated
by PKA and AKT [1,4].
Besides the conventional, Ras-induced C-Raf activation, several re-
ports also propose Ras-independent C-Raf activation modes. For exam-
ple, deletion of the N-terminal regulatory region that contains the Ras
binding domains results in an increased C-Raf kinase activity [21,22].
This form appears naturally as a viral-transmitted oncogene, however,
the fact that it can be further activated by growth factor stimulation,
suggests that modiﬁcations within the catalytic region itself are in-
volved in the normal activation process [23]. Another example is the
ability of PAK and Src family kinases to partially activate C-Raf in a
Ras independent manner by phosphorylating an auto-inhibitory C-Raf
regulatory region containing S338 and Y341 sites [24,25].
Protein kinase C family members, including PKC δ were reported
initially as Ras-independent C-Raf activators by showing that phorbol
esters can activate C-Raf in a manner not inhibited by a dominant
negative Ras form, Ras N17 [26,27]. However, a later study demon-
strated that mutations within the RBD domain completely abolished
C-Raf activation by phorbol esters [28]. Since phorbol esters strongly
activate Ras, it is possible that the dominant negative Ras was not suf-
ﬁcient in blocking the Ras-induced C-Raf activation. In addition, muta-
tions of the proposed PKC phosphorylation sites of C-Raf, S497/499, do
not affect C-Raf activation by growth factors or PMA [29].
During the initial elucidation of the MAPK pathway, early studies
reported C-Raf phosphorylation by ERK in vitro, but the functional sig-
niﬁcance of this phosphorylation was not determined [30,31]. Later
studies that established the signaling direction from Raf to MEK and
from MEK to ERK, diverted the focus from these initial observations
[5,32], however, they have been conﬁrmed in more recent studies
demonstrating that ERK phosphorylates C-Raf at multiple sites, in-
cluding S289, 296, 301 and S642, providing a feedback regulatory
mechanism [33,34]. Controversy remains, however, as to whether
this phosphorylation serves as a positive or negative regulation [1,4].
Our work points to a positive regulation of C-Raf by ERK-mediated
phosphorylation by stabilizing the active form of C-Raf [34]. It is im-
portant to note, however, that the ERK-mediated C-Raf phosphoryla-
tion does not activate C-Raf or enhances its activation by itself, but it
rather prolongs the activation duration induced by growth factors.
MEK-1 was also reported to positively regulate C-Raf: Alessandrini
et al. [35] showed that constitutively active forms of MEK-1 can in-
duce the transformation of NIH 3T3 and Swiss 3T3 cells and thatclonal cell lines expressing active MEK-1 mutants displayed elevated
C-Raf kinase activity. Conﬁrming these results, Zimmermann et al.
[36] reported that a constitutively active MEK-1 and to a lesser extent,
wildtypeMEK-1, can induce increased C-Raf phosphorylation. This in-
creased phosphorylation correlated with C-Raf activation (2-fold with
wildtype MEK and 6-fold with active MEK). The ability of active MEK
to induce C-Raf activation was not dependent on Ras or Src, but was
dependent on ERK kinase activity, suggesting a positive feedback loop
mediated by ERK.
Here, we provide conclusive evidence that MEK-1 is a potent, Ras-
independent C-Raf activator. Our data demonstrate that coexpression
of wildtype MEK-1 and C-Raf induces a strong increase in C-Raf phos-
phorylation, resulting in full activation of C-Raf kinase activity, similar
to that achieved with growth factors. Interestingly, the increased
C-Raf phosphorylation was due primarily to an increase in the basal
phosphorylation sites. The ability of MEK to induce C-Raf phosphory-
lation and activation required C-Raf binding and kinase activity, but
was only partially dependent on MEK-1 kinase activity itself. Impor-
tantly, wildtype MEK was able to fully activate C-Raf mutants im-
paired in Ras binding and was not affected by a dominant negative
Ras mutant, demonstrating complete independence of Ras. We pro-
pose that direct interaction of C-Raf and MEK-1 contributes to C-Raf
activation by inducing C-Raf hyper-phosphorylation, either by confer-
ring a conformation that is more susceptible to phosphorylation or by
stabilizing the phosphorylated form of C-Raf. These ﬁndings have
potential signiﬁcance in cancers that overexpress wildtype C-Raf
and MEK or in cases where RKIP [37] or MST2, which are natural
inhibitors of C-Raf–MEK interaction, are down-regulated.
2. Materials and methods
2.1. cDNA constructs, antibodies and kinase inhibitors
The bacterial expression vectors pGEX-GST–MEK-1 and GST-ERK-1
and the mammalian expression vectors pExchange 5a-FLAG-MEK-1,
pMT2-HA-ERK-1, pMT2-myc-C-Raf expressing wildtype or S471A/T,
S259/621A, S289/296/301A mutants and pCMV5-FLAG-Ras N17 or
V12 were described previously [12,15,18,34,38]. The QuikChange
site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used to
generate pMT2-myc-C-Raf mutants containing the following mutations:
S338/339A, K84A/L86A/K87A (Ras binding domain, RBD mutant),
C165/168S and C165/168A (cysteine rich domain, CRD mutants),
K375M (kinase-dead, KD mutant) and their combinations: RBD/CRD,
RBD/KD and RBD/CRD/KD. pExchange 5a-FLAG-MEK-1 was used as a
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domain deletion (Δ 265–301) and DVD mutants (W374D, L375E and
WL374/375DE). Antibodies for MEK and ERK and phosphospeciﬁc
antibodies for their active forms were from Cell Signaling Technology
(Beverly, MA), FLAG antibody was from Sigma (St. Louis, MO) and
antibodies for HA and myc epitope tags were produced from the
12CA5 and 9E10 hybridoma clones, respectively. Phosphospeciﬁc anti-
bodies for C-Raf pS296 were produced and screened for speciﬁcity as
described previously [34]. The MEK inhibitor U0126 was from Promega
(Madison, WI).
2.2. Cell culture and transfection
COS-7 cells were maintained in DMEM supplemented with 10% fetal
calf serum. For transient expression of proteins, cells were transfected
using LipofectAMINE (Invitrogen, Carlsbad, CA) as detailed in the ﬁgure
legends according to the manufacturer's instructions. For cell stimula-
tion, 24 h after transfection, cellswere deprived of serum for 18 h before
adding the agonist. Details for cell stimulation and drug treatments are
provided below and in the ﬁgure legends.
2.3. 32P metabolic labeling
Serum-deprived COS-7 cells transfected as indicated in the ﬁgure
legends were washed once with medium lacking phosphate, followed
by 30-min incubation in the phosphate-free media for depleting in-
tracellular phosphate. Cells were radio-labeled by incubation in the
presence of 0.5 mCi/ml 32P for 2 h as previously described [34].
2.4. Cell extraction and protein puriﬁcation
Cellswere lysed for 30 minusing ice-cold extraction buffer containing
50 mMTris–Cl, pH 7.5, 100 mMNaCl, 1% Triton X 100, 1 mMDTT, 1 mM
EDTA, 1 mM EGTA, 2 mM Na3VO4, 50 mM ß-glycerophosphate and
a protease inhibitor cocktail (Amersham, Piscataway, NJ). For immu-
noprecipitation, cleared cell lysates were incubated at 4 °C for 2 h with
the appropriate antibody precoupled to protein A/G agarose-beads
(SantaCruz, Santa Cruz, CA). The beads were washed twice with extrac-
tion buffer, twice with extraction buffer containing 0.5 M LiCl and twice
with kinase assay buffer (40 mM Tris–Cl pH 7.5, 0.1 mM EDTA, 5 mM
MgCl2 and 2 mMDTT). The puriﬁed proteins were used further as speci-
ﬁed in the ﬁgure legends.
2.5. C-Raf phosphopeptide mapping
Two-dimensional phosphopeptide mapping was performed
according to previously described protocols [39,40]. Brieﬂy, immuno-
puriﬁed 32P-labeled myc-C-Raf proteins were resolved using 7.5%
SDS-PAGE, transferred to a PVDF membrane, excised, and 32P incor-
poration in myc-C-Raf was determined by Cherenkov counting. Fol-
lowing incubation with 0.5% poly-vinyl-phosphate (PVP) in 100 mM
acetic acid for 30 min at 37 °C and extensive washes, C-Raf protein
samples were digested with 10 μg sequencing grade modiﬁed trypsin
(Promega, Madison, WI) in 50 mM ammonium bicarbonate buffer for
2 h at 37 °C and with additional 10 μg of trypsin for overnight
(this method routinely allowed recovery of 90–95% of the initial ra-
dioactivity in myc-C-Raf). The eluted peptides were washed twice
with 50 mM ammonium bicarbonate buffer and once with pH 1.9
TLC-electrophoresis buffer (2.2% Formic acid and 7.8% acetic acid in
water). Sampleswere spotted on cellulose TLC plates (Merck, Darmstadt,
Germany) and separated using the Hunter thin-layer chromatography
system (CBS Scientiﬁc, Del Mar, CA) in pH 1.9 buffer for 25 min at
1000 V. The plateswere dried overnight and subjected to second dimen-
sion chromatographic separation in a phospho-chromatography buffer
(37.5% n-Butanol, 25% Pyridine and 7.5% acetic acid). The plates were
dried and the phosphopeptide spotswere visualized by autoradiographyand phosphor-imaging. Each experiment was repeated at least three
times and representative maps are presented.
2.6. C-Raf kinase assay
C-Raf kinase activity was determined using a slight modiﬁcation of
a previously described protocol [18,34]. Brieﬂy, following myc immu-
noprecipitation, myc-C-Raf containing beads were incubated in ki-
nase assay buffer (100 μl ﬁnal volume) supplemented with 100 μM
ATP, and 0.4 μg prokaryotic recombinant GST–MEK-1-His for 30 min
at 30 °C. Samples were separated on 10% SDS-PAGE and transferred
to PVDF membranes. The phosphorylation of MEK-1 was determined
by phospho-MEK-immunoblotting or using 32P ATP in the kinase re-
action and densitometry quantiﬁcation. In some cases, Raf kinase ac-
tivity was determined in a coupled kinase assay, where 1 μg GST–ERK
was added to the kinase reaction and incubated for additional 30 min
as previously described [18]. myc-C-Raf recovery was determined by
myc-immunoblotting. Each kinase experiment was repeated at least
three times and representative kinase experiments are presented.
3. Results
3.1. Coexpression of wildtype C-Raf and MEK-1 results in increased C-Raf
phosphorylation and kinase activity
In the course of studying C-Raf–MEK-1 interactions, we noticed
that coexpression of C-Raf with MEK-1 results in a signiﬁcant mobil-
ity shift in C-Raf, suggesting that MEK-1 could induce increased C-Raf
phosphorylation [18]. To test this possibility, we examined the effect
of MEK-1 on C-Raf phosphorylation using 32P-metabolic labeling
and 2D phospho-peptide mapping of C-Raf (Fig. 2). Surprisingly,
MEK-1 expression induced a much stronger C-Raf phosphorylation
than the one observed with growth factors, reaching up to a 10-fold
increase in overall C-Raf phosphorylation (Fig. 2a, compare lanes 1,
2 and 11 and Fig. 2b, lanes 1, 2 and 5). To examine whether this in-
crease was due to new phosphorylation sites or due to an increase
in the basal sites, C-Raf phosphorylation was analyzed using 2D
phosphopeptide mapping (Fig. 2b). Note that we loaded equal counts
of trypsin-digested C-Raf peptides from the various samples in this
analysis (1500–2000 cpm) in order to be able to compare the relative
stoichiometry of the various phosphorylation sites. Therefore, the
MEK-induced increases in overall C-Raf phosphorylation do not ap-
pear in the maps. This analysis revealed that the MEK-induced in-
crease in C-Raf phosphorylation derived primarily from an increase
in the basal C-Raf phosphorylation sites rather than from phosphory-
lation at new sites (Fig. 2b, compare panels 1 and 5). Although we
observed several new C-Raf phosphorylation sites in the MEK-1
coexpressing cells (Fig. 2b, panel 9, spots n, x, y and z), these sites
accounted only for a small fraction of the overall C-Raf phosphoryla-
tion. Importantly, MEK-1 did not induce the phosphorylation of
C-Raf S471A and S471T mutants that abrogate MEK-1 binding [18]
(Fig. 2a, compare lanes 1 and 11 (wildtype C-Raf) with lanes 3 and 9
(S471A) or with lanes 5 and 10 (S471T) and Fig. 2b, compare lanes 1
and 5 (wildtype) with lanes 3 and 6 (S471A)). This result indicates
that MEK-1 binding to C-Raf is required for the enhanced C-Raf phos-
phorylation, suggesting that MEK-1 may confer a C-Raf conformation
that is more accessible to phosphorylation or is protected from de-
phosphorylation. In addition, C-Raf activity itself was not required
for the ability of MEK-1 to induce C-Raf phosphorylation, since the in-
crease in phosphorylation was also observed with an inactive C-Raf
mutant, C-Raf S259/621A [15] (Fig. 2b, compare lanes 7 and 8). Simi-
larly, MEK kinase activity also appeared to play a minor role, since
treatment with the MEK inhibitor U0126 had a small effect on the
enhanced C-Raf phosphorylation (Fig. 2a, compare lanes 8 and 11).
Overall, these experiments support the notion that MEK-1 increases
Fig. 2.MEK-1 expression induces increased C-Raf phosphorylation. (a) COS-7 cells were transfected with pMT2-myc-C-Raf wildtype (wt), S471A or S471T mutants alone (lanes 1–
7) or together with pExchange 5a-FLAG-MEK-1 (lanes 8–11). Following 24 h, cells were deprived of serum for 18 h, metabolically labeled with 32P and treated with vehicle or
100 ng/ml EGF for 30 min. Indicated samples (lanes 7 and 8) were treated with 20 μM of the MEK inhibitor, U0126, 30 min prior to 32P-labeling. myc-C-Raf proteins were
immunoprecipitated with a myc-epitope tag antibody and separated using SDS-PAGE. 32P incorporation in myc-C-Raf was visualized using a phosphor imager (inset) and quantiﬁed
using the Bio-Rad Quantity One software. (b) Cells were transfected as indicated and the samples were analyzed as in a (left top panel). The 32P bands were excised from the mem-
brane and 2D phosphopeptide mapping was performed as described in Materials and methods (panels 1–8). 10% of the sample was used to examine myc-C-Raf recovery (bottom
part). A schematic representation of the phosphopeptide spots, including the migration positions of known C-Raf phosphopeptides are depicted in panel 9. Arrows indicate the ori-
entation of electrophoresis and TLC chromatography. Note that equal amounts of counts were loaded from each sample (1200 cpm, excluding sample 7) to allow comparison of
phosphorylation stoichiometry between the samples. For sample 7, S259/621A mutant, only 300 cpm was available since this mutant is consistently less phosphorylated than
the other C-Raf forms. The results are representative of three independent experiments.
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of C-Raf or MEK-1 kinase activities.
Since C-Raf phosphorylation has been correlated with its kinase
activity, we examined next the effect of MEK-1 expression on the
intrinsic kinase activity of C-Raf (Fig. 3). In these experiments, myc-
epitope-tagged C-Raf puriﬁed from serum-deprived COS-7 cells ex-
pressing C-Raf alone or from cells coexpressing C-Raf with MEK-1
was assayed in vitro for kinase activity using recombinant bacterially-
expressed GST–MEK-1 as a substrate. Surprisingly, coexpression of
MEK-1 was sufﬁcient to induce same extent of C-Raf activation in
serum-deprived cells as the one achieved with EGF stimulation (Fig. 3,
compare lanes 2 and 3). We did not observe much additive effect of
EGF and MEK-1 on C-Raf activation (Fig. 3, lane 4). We showed previ-
ously a positive feedback regulation of C-Raf by ERK-mediated C-Raf
phosphorylation [34]. Notably, in this work, ERK did not activate c-Raf
per se and it did not enhance the basal kinase activity of C-Raf inunstimulated cells, rather, it was able to prolong the activation duration
of C-Raf in cells stimulated by growth factors. To examine the role of
ERK in the MEK-induced C-Raf activation, we used a mutant of C-Raf,
S289/296/301A, lacking the ERK phosphorylation sites and also
coexpressed ERK with MEK and C-Raf (Fig. 3). ERK overexpression did
not affect the extent of C-Raf activation by either EGF or MEK (Fig. 3,
compare lanes 1–4 and 5–8). However, the S289/296/301A C-Raf mu-
tant showed decreased activation by MEK compared to wildtype C-Raf
(Fig. 3, compare lanes 3 and 11), suggesting that the ERK-induced phos-
phorylation and/or these sites play some role in theMEK-induced C-Raf
activation process.
Together, these results point to MEK-1 as a novel C-Raf activator,
which is able to activate C-Raf in the absence of growth factors and
as efﬁciently as the conventional growth factor receptor-Ras pathway,
possibly by directly binding C-Raf and increasing its basal phosphory-
lation. Of note, incubation of C-Raf puriﬁed from serum-deprived cells
Fig. 3. MEK-1 expression increases C-Raf kinase activity. COS-7 cells were transfected
with pMT2-myc-C-Raf (wt) or S289/296/301Amutant alone or together with pExchange
5a-FLAG-MEK-1 or pMT2-HA-ERK1 as indicated. After 24 h, cells were deprived of serum
for 18 h and treated with vehicle or 100 ng/ml EGF for 20 min. C-Raf kinase activity
in myc-immunoprecipitates was assayed using recombinant GST–MEK-1 as a substrate
as described in Materials and methods. Presented are phospho-MEK and myc immuno-
blots showing MEK phosphorylation and myc-C-Raf recovery, respectively. The bar
graph shows densitometry quantiﬁcation of the phospho-GST–MEK-1 band. Presented
are representative results of three independent experiments.
Fig. 4. Coexpression of MEK-1 and C-Raf induces constitutive activation of MEK and
ERK. (a) COS-7 cells were transfected with wildtype pMT2-myc-C-Raf (wt, lanes 1, 2
and 5, 6), the S471A mutant (471A, lanes 7, 8) or empty pMT2 vector (lanes 3, 4),
alone (lanes 1, 2) or together with pExchange 5a-FLAG-MEK-1 (lanes 3–8). After
24 h, cells were deprived of serum for 18 h and treated with vehicle or 100 ng/ml
EGF for 20 min as indicated. MEK-1 activation in cells was determined following FLAG
immunoprecipitation and immunoblotting with phospho-MEK (top panel). MEK-1 re-
covery was examined by FLAG-immunoblotting (middle panel) and myc-C-Raf expres-
sionwas determined in cell extracts bymyc immunoblotting (bottom panel). (b) COS-7
cells expressing the above C-Raf and MEK-1 expression vectors, as indicated, together
with pMT2-HA-ERK-1 vector were stimulated with EGF as in a. ERK phosphorylation
was determined following HA immunoprecipitation (top panel). ERK recovery was de-
termined using HA immunoblotting. MEK and Raf expressions were determined in cell
lysates using FLAG and myc immunoblotting respectively. Presented are representative
results of ﬁve independent experiments.
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that theMEK-induced C-Raf activation is dependent on cellular factors
that promote C-Raf activation in vivo.
3.2. Coexpression of wildtype C-Raf and MEK-1 results in constitutive
activation of the ERK–MAPK pathway
To examine the cellular consequences of the ability of MEK-1 to
induce C-Raf activation, we examined the phosphorylation of MEK-1
and ERK on their activation sites in COS-7 cells (Fig. 4). In these
experiments, FLAG-epitope-tagged MEK-1 was coexpressed with
wildtype or the S471A C-Raf mutant that does not bind MEK-1 and
MEK-1 phosphorylation was determined by immunoblotting with
activation-speciﬁc phospho-MEK antibodies (Fig. 4a). C-Raf expres-
sion with MEK-1 resulted in MEK-1 phosphorylation, reaching almost
same levels as achieved with EGF stimulation (Fig. 4a, compare lanes
3, 4 and 5, 6). The inactive S471A C-Raf mutant, that does not bind
MEK, did not induce MEK phosphorylation (Fig. 4a, compare lanes 6
and 8), indicating that both C-Raf kinase activity and MEK binding
are required. In complementary experiments, we used HA-ERK-1 as
readout for MEK activity, showing that coexpression of wildtype
C-Raf and MEK-1 induces strong ERK-1 phosphorylation (Fig. 4b,
compare lanes 1, 2 with 5, 6). Also in these experiments, the S471A
C-Raf mutant was unable to activate the pathway (compare lanes 1,
2 with 3, 4).
To determine the extent of C-Raf/MEK overexpression needed
to achieve constitutive activation of the pathway, increasing amountsof C-Raf, MEK-1 or ERK-1 were expressed in COS-7 cells and the acti-
vation of the pathway was determined in cells (Fig. 5a) and in vitro
(Fig. 5b and c). These experiments showed sensitivity to small in-
creases in C-Raf expression that were sufﬁcient to induce full ERK
phosphorylation when MEK-1 was coexpressed (Fig. 5a, compare
lanes 1–5 and 6–10 or 11–15). MEK-1 by itself did not activate ERK
(Fig. 5a, lanes 16 and 33). Similar results were obtained when C-Raf
activity was measured in vitro (Fig. 5b and c, lanes 1–6). However,
maximal C-Raf activation in vitro was reached only with maximal
MEK-1 expression, suggesting lower sensitivity of the in vitro assay.
As seen in Fig. 3, ERK overexpression did not alter the extent of
C-Raf activation by MEK (Fig. 5b, compare lanes 1–6 with 7–12 and
13–18). These experiments have been repeated in several other cell
lines including NIH3T3, HEK293 and the immortalized prostate
Fig. 5. Small increases inMEK-1 and C-Raf expression are sufﬁcient for ERK activation. (a) COS-7 cells were transfected with the indicated amounts of pExchange 5a-FLAG-MEK-1 and
pMT2-HA-ERK-1 together with increasing amounts of pMT2-myc-C-Raf (0.01–1 μg/plate). After 24 h, cells were deprived of serum for 18 h and treated with vehicle or 100 ng/ml
EGF for 20 min, where indicated. ERK-1 activation in cells was determined by immunoblotting for phospho-ERK (top panel). Expression of myc-C-Raf, FLAG-MEK and HA-ERK was
examined by myc, FLAG and HA immunoblotting, respectively. Note that increased expression of myc-C-Raf resulted in decreased HA-ERK expression. This was probably due to DNA
interference since both use the pMT2 backbone. Empty pMT2 vector was used to adjust for total DNA amounts in these transfections. (b and c) COS-7 cells were transfected with
pMT2-myc-C-Raf and the indicated amounts of pMT2-HA-ERK-1 together with increasing amounts of pExchange 5a-FLAG-MEK-1 (0.01–1 μg/plate). After 24 h, cells were deprived
of serum for 18 h and C-Raf kinase activity was examined in vitro in myc immunoprecipitates using recombinant GST–MEK-1 as a substrate and 32P-ATP (b, top panel). myc-C-Raf
recovery, MEK and ERK expressions are also provided (b). Quantiﬁcation of GST–MEK phosphorylation is provided in c. Presented are representative results of three independent
experiments.
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pointing to the universality of this mechanism. These results demon-
strate that constitutive activation of the Raf–MEK–ERK pathway can
be achieved without a mutation in the pathway, but simply by co-
overexpression of wildtype MEK and C-Raf.
3.3. MEK-1-induced C-Raf activation is Ras independent
To examine the role of Ras in the MEK-1-induced C-Raf activation,
we used C-Raf mutants impaired in Ras binding. These included the
Ras-binding domain (RBD) mutant, C-Raf K84A/L86A/K87A that im-
pairs binding to Ras switch I region, the cysteine-rich domain (CRD)
mutant, C-Raf C165/168S that impairs binding to farnesylated-Ras
and a double, RBD/CRD mutant. These mutants were previously
shown to be completely inactive in cells treated with various growth
factors, when coexpressed with active Ras or when activation wasinduced by dimerization [12,29,38]. To examine the activation of the
Ras-binding C-Raf mutants by MEK-1 in cells, the mutants were
coexpressed in COS-7 cells with MEK-1 and their activation was
determined by immunoblotting with phospho-speciﬁc MEK-1 anti-
bodies (Fig. 6a). Both the RBD and CRD C-Raf mutants, either native
or membrane-targeted by the CaaX motif, were able to induce MEK
phosphorylation to the same extent as wildtype C-Raf or EGF stimula-
tion (Fig. 6a, compare lane 3 with 4, 5 and lane 6 with 7, 8). As noted
in previous studies, the CaaX forms have higher intrinsic catalytic
activity than wildtype C-Raf forms.
To further examine the Ras-independent activation of the MAPK
pathway in cells, ERK-1 was coexpressed with the Ras-binding C-Raf
mutants and their effect on ERK-1 phosphorylation was determined
(Fig. 6b). These experiments conﬁrmed the ability of the RBD/CRD
C-Raf mutants to fully activate the cascade when coexpressed with
MEK (Fig. 6b, lanes 1–13). Importantly, full activation of the pathway
Fig. 6.MEK-induced C-Raf activation is Ras-independent. (a) COS-7 cells were transfected
with pExchange 5a-FLAG-MEK-1 alone (lanes 1,2) or togetherwith pMT2-myc-C-Raf (wt)
or K84A/L86A/K87A (RBD, Ras binding domain), C165/168S (CRD, cysteine-rich domain)
C-Raf mutants or with same C-Raf forms containing a c-terminal CaaX motif for mem-
brane targeting (caax). After 24 h, cells were deprived of serum for 18 h and treated
with vehicle or with 100 ng/ml EGF for 20 min as indicated. Presented are a pMEK immu-
noblot of FLAG-immunoprecipitates, a MEK immunoblot showing MEK recovery and a
myc immunoblot showing the expression of the myc-C-Raf variants. (b) COS-7 cells
were transfected as in a with the indicated DNA combinations of MEK, C-Raf variants
and pMT2-HA-ERK. Presented are a pERK immunoblot in cell extracts and amyc immuno-
blot showing the expression of the myc-C-Raf variants. CRD/SA is C165/168A mutant,
RBD/KD and RBD/CRD/KD are RBD and RBD/CRD mutants, respectively, that include
also the K375M mutation in the ATP binding pocket that abrogates C-Raf kinase activity
(see materials and methods for more details). Presented are representative results of
four independent experiments.
Fig. 7. Additive C-Raf activation by MEK and Ras. (a) COS-7 cells were transfected with
pMT2-myc-C-Raf (wt) or K84A/L86A/K87A (RBD), C165/168S (CRD), K375M (KD) or
their indicated combinations, alone or with pExchange 5a-FLAG-MEK-1 as indicated.
After 24 h, cells were deprived of serum for 18 h and C-Raf kinase activity was deter-
mined in myc-immunoprecipitates using an in vitro kinase assay with recombinant
GST–MEK as a substrate. Presented are amyc immunoblot showingmyc-C-Raf recovery
(top panel) pMEK immunoblot of the GST–MEK substrate (middle panel) and FLAG im-
munoblot of cell extracts showing FLAG-MEK expression in the cells (bottom panel).
(b) COS-7 cells were transfected with pMT2-myc-C-Raf (wt) or the RBD/CRD mutant
together with pExchange 5a FLAG-MEK-1 and pCMV5-FLAG-Ras V12 (V, constitutively
active) or N17 (N, inactive mutant) as indicated. After 24 h, cells were deprived of
serum for 18 h and treated with vehicle or with 100 ng/ml EGF for 20 min. Presented
are a pMEK immunoblot of cell extracts (top panel), a myc immunoblot showing the
expression of myc-C-Raf variants (middle panel) and a FLAG immunoblot showing
the expression of the FLAG-Ras variants (bottom panel). The results are representative
of two independent experiments.
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complete independence from Ras binding in the MEK-induced C-Raf
activation (Fig. 6b, lane 14). As an additional control, the Ras-binding
mutations were introduced into the background of an ATP-binding
site C-Raf mutant, K375M. This control demonstrated that the Ras-
independent activation remained dependent on C-Raf kinase activity
(Fig. 6b, lanes 15–18).
In addition to examining the activity of the Ras-binding C-Raf mu-
tants in cells, we also measured their activity in vitro (Fig. 7a). These
experiments conﬁrmed the in situ experiments and demonstrated
that MEK-1 can fully activate the Ras-binding C-Raf mutants (Fig. 7a,
compare lane 2 with 4, 6, 8), indicating that C-Raf activation by MEK
overexpression does not require direct C-Raf interaction with Ras.
The K375M mutation eliminated the observed kinase activity also in
this assay.
As a complementary approach to examine the role of Ras in the
MEK-1-induced C-Raf activation, we used the dominant negative
and constitutively active Ras forms, Ras N17 and Ras V12, respectively.
In these experiments, COS-7 cells were coexpressed with MEK-1 and
C-Raf along with Ras N17 or Ras V12 and their effects on MEK-1 phos-
phorylation in the cell were examined (Fig. 7b). The dominant nega-
tive Ras N17 had no effect on the ability of either wildtype C-Rafor the RBD/CRD C-Raf mutant to induce MEK-1 phosphorylation
(Fig. 7b, compare lanes 5 and 12with 6 and 13). Importantly, however,
the active Ras V12 cooperated withMEK for wildtype C-Raf activation,
but had no effect on the double RBD/CRD C-Raf mutant (Fig. 7b, com-
pare lanes 7 and 14). This experiment suggests that MEK and Ras may
be utilizing parallel independent pathways for C-Raf activation.
3.4. MEK-1-induced C-Raf activation is not dependent on MEK kinase
activity
To examine the role of MEK-1 kinase activity in the MEK-1-
induced C-Raf activation, we tested the effects of an inactivating
MEK-1 mutation, K97M, on the ability of MEK-1 to activate C-Raf
(Fig. 8). These experiments demonstrated that the kinase-dead
MEK-1 mutant induced similar C-Raf activation to the one seen with
wildtype MEK-1 (Fig. 8a, compare lanes 13, 14 with 15, 16). As
expected, the kinase inactive MEK-1, though being phosphorylated
by C-Raf, did not result in ERK activation (Fig. 8a, pERK blot, compare
lanes 9, 10 with 11, 12). Also when assayed in vitro, the kinase-dead
MEK-1 mutant induced similar C-Raf activation as achieved with
wildtype MEK-1 (Fig. 8b, compare lane 1 with 7), conﬁrming that
MEK-1 activity plays only a minor or no role in the MEK-1-induced
C-Raf activation.
Fig. 8. MEK kinase activity is not required for the MEK-induced C-Raf activation. (a) COS-7 cells were transfected with pMT2-myc-C-Raf together with pMT2-HA-ERK-1 and
pExchange 5a-FLAG-MEK-1 wildtype (wt) or a kinase dead mutant (KD, K97M) as indicated. After 24 h, cells were deprived of serum for 18 h and treated with vehicle
or 100 ng/ml EGF for 20 min. Presented are phospho-MEK and phospho-ERK immunoblots of cell lysates showing MEK and ERK phosphorylation, respectively and FLAG, HA
and myc-immunoblots showing FLAG-MEK-1, HA-ERK-1 and myc-C-Raf expression. (b) COS-7 cells were transfected with pMT2-myc-C-Raf together with pExchange
5a-FLAG-MEK-1 (wt, lanes 7, 8) or K97M mutant (KD, lane 1) as indicated. After 24 h, cells were deprived of serum for 18 h in the presence or absence of the heat-shock protein
90 inhibitor 17-AAG (1 μM) and treated with vehicle or 100 ng/ml EGF for 20 min. C-Raf kinase activity was measured in vitro in myc-immunoprecipitates using a coupled kinase
assay with recombinant ERK-1 serving as a substrate. Presented are phospho-ERK and myc immunoblots of the kinase reaction showing Raf kinase activity and myc-C-Raf recovery
and phospho-MEK and FLAG immunoblots of cell extracts showing MEK phosphorylation and expression in cells. Alpha-tubulin immunoblot shows equal protein loading. Note that
17-AAG treatment results in reduced myc-C-Raf and FLAG-MEK protein expressions (lanes 4, 6, 8) as has been previously reported. (c) COS-7 cells were transfected with
pMT2-myc-C-Raf (wt) or S338/339A mutant together with pMT2-HA-ERK-1 and pExchange 5a-FLAG-MEK-1 wildtype (wt) or a proline-rich domain deletion mutant (Δ, deletion
of amino acids 265–301) as indicated. After 24 h, cells were deprived of serum for 18 h and treated with vehicle or 100 ng/ml EGF for 20 min. Following protein extraction, samples
were split and half was used to immunoprecipitate MEK using FLAG antibody (left part) and half to immunoprecipitate Raf using myc antibody (right part). In the left part,
presented are FLAG, myc and pS296 C-Raf immunoblots in FLAG-immunoprecipitates (FLAG-IP), showing FLAG-MEK, myc-C-Raf and phospho-S296 C-Raf recoveries, respectively,
and a pERK immunoblot of cell extracts, showing ERK phosphorylation in cells. In the right part, presented are pS338 C-Raf and myc immunoblots in myc-immunoprecipitates
(myc-IP), showing C-Raf phosphorylation at the S338 site and myc-C-Raf recovery. Note that the Δ 265–301 MEK-1 mutant activates and binds C-Raf as efﬁciently as full-length
MEK-1.
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C-Raf and to inhibit its kinase activity [41] was also able to destabilize
and inhibit C-Raf coexpressedwithMEK-1 (Fig. 8b, lane 8), suggesting
that MEK-1 does not replace the need for interaction with HSP-90.
The lack of a role for MEK kinase activity in C-Raf activation com-
bined with the observation that phosphorylation of the C-Raf S471A
mutant that does not bind MEK-1 was unaffected by coexpression
with MEK-1 (Fig. 2), led us to hypothesize that MEK-1 could be
enhancing C-Raf phosphorylation and C-Raf activity through direct
binding. To address this point, we attempted to generate MEK-1 forms
impaired in C-Raf binding. Several previous reports claimed the identi-
ﬁcation of the C-Raf binding point on MEK. The reported sites include a
proline-rich domain spanning amino acids 265–301 of MEK-1 [42], and
a short domain deﬁned as a domain for versatile docking (DVD), com-
prising amino acids 358–382 of MEK-1, that was suggested to be auniversal domain mediating MAP2K binding to MAP3Ks [43]. Unfortu-
nately, after generating a MEK-1 265–301 deletion as well as MEK-1
DVD mutants (W374D, L375E and WL374/375DE), which were previ-
ously shown to eliminate MEK phosphorylation by active Raf andmito-
gens and examining their binding to C-Raf, we found that thesemutants
bound and activated C-Raf as potently as wildtype MEK-1 (Fig. 8c and
data not showed). For example, FLAG-MEK-1 265–301 deletionmutant
when coexpressed with myc-C-Raf, induced similar ERK phosphoryla-
tion as full-length MEK-1. The deletion mutant was also able to
co-immunoprecipitate equal amounts of C-Raf as full-length MEK-1
(Fig. 8c, compare lanes 6, 7 and 9). Control FLAG immunoprecipitation
from cells expressing only myc-C-Raf, did not recover a detectable
myc-C-Raf signal (Fig. 8c, lanes 2, 3 and 6). Interestingly, C-Raf recov-
ered in the MEK-1 immunoprecipitates was phosphorylated at the
S296 site we previously showed to be present on active C-Raf [34]
Fig. 9. A model for Ras-independent C-Raf–MEK activation. In normal conditions C-Raf
and MEK expressions are low and they are maintained apart by cellular factors such as
RKIP and MST2 (a). In certain conditions, such as cancer, increased expression of Raf
and MEK (b) or down-regulation of the sequestering factors (c) allows increased
C-Raf–MEK binding, resulting in C-Raf hyper-phosphorylation and activation.
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C-Raf phosphorylation at the S338 site, which was shown to play a role
in C-Raf activation by certain growth factors [19], MEK-1 was able to
bind and activate the S338/339A C-Raf mutant, suggesting that the
MEK-1-induced C-Raf activation does not require phosphorylation at
these sites (Fig. 8c, lanes 4, 5, left panel and lanes 6–9, right panel).
4. Discussion
C-Raf is subjected to tight regulation in the cell, however, its in-
creased activation is common in many cancers and is associated with
cellular transformation [1]. Many studies have linked upregulated
C-Raf activity in cancers with the presence of activating Ras mutations
or increased activation of tyrosine-kinase receptors, especially EGF
receptor family members [8]. Ras has been established as a primary
activator of C-Raf and alternative pathways for C-Raf activation have
not been widely accepted by the scientiﬁc community. In addition,
overexpression of C-Raf is not considered by-itself tumorigenic, since
it does not result in C-Raf activation or activation of its downstream
mediators, MEK and ERK [3,22,44]. The present study provides com-
pelling evidence supporting the existence of an alternative pathway
for C-Raf activation that does not involve Ras. Our results demonstrate
that elevated coexpression of wildtype C-Raf and MEK-1 in cells re-
sults in increased C-Raf phosphorylation, leading to enhanced C-Raf
kinase activity, which in turn activates the downstream effectors MEK
and ERK. Our data also unequivocally show that the MEK-induced
C-Raf activation is completely Ras independent, requires intact S471
and S621 phosphorylation sites, but not the S338/339 sites. In addition,
this activation is only partially dependent on MEK kinase activity and
does not require new transcription or translation (data not showed).
Importantly, modest increases inMEK and C-Raf coexpression are sufﬁ-
cient formaximal activation of ERK in vivo, suggesting clinical relevance
in pathological conditionswhereMAPK activation is not associatedwith
Ras mutations or over-activation of tyrosine kinase receptors.
Several studies examining C-Raf and MEK expressions in clinical
samples noted increased expression in cancer specimens. For example,
increased C-Raf expression has been documented in acute myeloid leu-
kemia (AML) [45], primitive neuroectodermal tumors (PNETs) [46],
non-small cell lung cancer (NSCLC) [47], ovarian cancer [48], thyroid
[49] and gliomas [49]. In addition, though early studies asserted that
overexpression of wildtype C-Raf or MEK is not tumorigenic, more
recent work indicates that targeted overexpression of wildtype C-Raf
in the lung could lead to lung cancer [50–54], suggesting that over-
expression of wildtype C-Raf is sufﬁcient for inducing cellular transfor-
mation. Our ﬁndings are of special signiﬁcance since they imply that
mutations along the pathway may not be necessary for constitutive
pathway activation, but rather co-overexpression of C-Raf with MEK
could sufﬁce. Since initial reports indicated that overexpression of na-
tive C-Raf or MEK alone did not lead to constitutive activation of the
MAPK pathway or cell transformation, few studies have looked for
overexpression of Raf or MEK proteins in human cancers. Our report
calls for reevaluating this premise and for a detailed examination of
Raf and MEK expression levels in human cancers.
As noted in the Introduction, the current view of C-Raf activation
does not give much weight to mechanisms that do not involve Ras.
Indeed, besides the work by Zimmermann et al. [36], there have not
been much credible or undisputed studies demonstrating C-Raf acti-
vation independent of Ras. The study by Zimmermann et al., though
providing substantial evidence for such a pathway through MEK, sur-
prisingly has not attracted enough attention in the ﬁeld to establish
this observation as a novel alternative mode for C-Raf activation and
has not been followed up by conﬁrming studies that further detail
this novel activation mechanism. The results presented in the present
study provide a more comprehensive description and analysis of this
novel mechanism and help in establishing this mode as a novel path
for C-Raf activation. In addition, the work by Zimmermann et al.pointed to ERK as the potential mediator of the activation, however,
our results indicate that the activation is largely independent of
MEK and ERK kinase activities, but rather may involve direct associa-
tion of MEK with C-Raf, leading to enhanced C-Raf phosphorylation
through increased susceptibility to phosphorylation or protection
from dephosphorylation.
A couple of recent studies also proposed Ras-independent activa-
tion of ERK through the conventional Raf–MEK pathway, however,
the exact mechanism of Raf activation has not been determined in
these studies [55,56].
As noted above, the relevance of MEK ability to activate C-Raf and
theMAPK pathway could be of physiological importance in pathological
conditions that show increased MEK and C-Raf expression or alterna-
tively, in cases that have decreased expression of the tumor suppressor,
Raf kinase inhibitor protein, RKIP, which is a prevalent phenomenon in
prostate [57] as well as several other cancers, such as thyroid, colorectal
and pancreatic cancers as well as in myeloid leukemias [58–62]. RKIP is
a natural inhibitor ofMEK–Raf interaction, functioning bydirect binding
to C-Raf and blocking MEK binding [37]. Increased expression of
RKIP leads to inhibition of MAPK activation and RKIP down-regulation
increases MAPK activation. In natural conditions, there is not much
C-Raf–MEK association, suggesting that the two proteins are kept
separate. However, when we co-overexpressed C-Raf and MEK, they
were easily co-puriﬁed, suggesting that their segregationwas overcome
by the overexpression. A recent unpublished work from Walter Kolch
(personal communication) demonstrated that MST2 may function in a
similar way to RKIP by blocking Raf–MEK binding and that RASSF1A
regulates this axis. We propose a model where C-Raf and MEK activa-
tion can be achieved by overexpression of the proteins or alternatively,
by decreased expression of RKIP or MST2, or increased expression of
RASSF1A, in a Ras independent manner (Fig. 9). Thus, in cancers that
have decreased expression of RKIP or MST2, the MAPK pathway may
be active in a Ras independent manner and the Raf–MEK interaction
could be considered for therapeutic intervention. This point is of special
importance since recent studies indicate fast resistance development to
Raf kinase targeting therapies [63–66].
C-Raf can be found in complex with several co-factors and adapter
proteins such as 14-3-3, HSP-70 and HSP-90, scaffolds such as KSR and
can also be found as homo- or hetero-dimers with B-Raf [1–3,67]. The
present study adds MEK-1 as an additional C-Raf interacting protein
that besides serving as a substrate also serves as a positive regulator
of C-Raf, augmenting its phosphorylation and activity.
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three decades, the mechanistic aspects of C-Raf association with its
partners, its dynamics and regulation, with the exception of Ras and
the 14-3-3 proteins, is not well established. For example, the sites
that mediate C-Raf homo- or the hetero-dimerization with B-Raf,
have not been determined, limiting the understanding of the func-
tional role of Raf dimerization in its regulation [3,68,69]. In this con-
text, a study by Rushworth et al., using overlapping peptide libraries
corresponding to the entire C-Raf and B-Raf sequences, identiﬁed nu-
merous Raf-derived peptides that can bind full-length B- and C-Raf,
suggesting that there are many binding points that contribute to
Raf homo- and hetero-dimerization [69]. The binding of C-Raf with
MEK is even less studied. Our previous work identiﬁed C-Raf S471
as a critical site for MEK binding [18] and the analog site in A-Raf
was shown later to mediate the binding of A-Raf with MEK [70].
There may be, however, other sites on Raf that contribute to MEK
binding that remains to be identiﬁed. In addition, there are no predic-
tions or proposed ideas for the nature of the Raf–MEK complex either
alone or in conjunction with other complex components. Though
several sites on MEK have been reported to mediate the binding to
C-Raf, namely the proline rich domain [42] and the DVD domain
mentioned above [43], our results indicate that deletion of the pro-
line rich domain and mutations at the DVD domain of MEK-1 do
not have an effect on C-Raf binding or the ability of MEK to activate
C-Raf.
While the present work does not establish the exact mechanism
by which MEK activates C-Raf, the data suggests that it involves
increased C-Raf phosphorylation. It remains to be determined, how-
ever, whether this increased phosphorylation involves stabilization
of the phosphorylated form by protecting C-Raf from dephosphoryla-
tion or by increasing its accessibility to kinases and phosphorylation.
Also, generating MEK-1 mutants that actually block interaction with
C-Raf could help in determining the role of MEK–C-Raf interaction
in the MEK-induced C-Raf activation. This point is of special signiﬁ-
cance since our data point to minimal role of MEK kinase activity in
this process.
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